Calcium-blocking technology
Stable-capping permanently blocks free aldehydes to prevent calcium binding within the tissue9,10
KONECT RESILIA aortic valved conduit
RESILIA tissue is designed for durability*
RESILIA tissue technology is backed by a strong, growing base of clinical evidence attesting to its haemodynamic performance and durability.10,11
Glycerolization
Glycerol displaces water in the tissue and preserves tissue integrity, which enables dry storage9
*As compared to self-assembled valved conduits with non-RESILIA valves.
The tissue advantage
*As compared to self-assembled valved conduits with non-RESILIA valves.
Edwards Lifesciences’ integrity preservation technology transforms bovine pericardial tissue into RESILIA tissue, effectively eliminating free aldehydes, while protecting and preserving the tissue.12
RESILIA tissue is designed to neutralize these binding sites, addressing one of the primary mechanisms of long-term valve failure.12
Clinically stable haemodynamics
RESILIA tissue valve cohorts observed excellent outcomes and stable haemodynamic performance through 7 years.11
Experience the RESILIA tissue portfolio difference
KONECT RESILIA aortic valved conduit brochure
References
- Calderon-Rojas R, Bagameri G, Schaff HV, et al. Early experience with a prefabricated bioprosthetic aortic valved conduit: The first 100. JTCVS Open. 2025;26:34-43
- Podesser BK, De Paulis R. Implantability of a novel, pre-assembled aortic valved conduit with RESILIA™ tissue. J Cardiovasc Surg. 2020;61(3)
- Bourguignon T, Bouquiaux-Stablo AL, Candolfi P, et al. Very long-term outcomes of the Carpentier-Edwards Perimount valve in aortic position. Ann Thorac Surg. 2015;99(3):831-7
- Bourguignon T, Lhommet P, El Khoury R, et al. Very long-term outcomes of the Carpentier-Edwards Perimount aortic valve in patients aged 50-65 years. Eur J Cardiothorac Surg. 2016;49(5):1462-8
- Fu Y, Guidoin R, De Paulis R, et al. The Gelweave Valsalva Graft to Better Reconstruct the Anatomy of the Aortic Root. J Long Term Eff Med Implants. 2016;26(2):97-121
- DeRoo SC, Desai N, Grimm JC, et al. In-human implantation of a novel biologic valved conduit for aortic root replacement. Ann Thorac Surg. 2022;113(1):e21-e24
- Urbanski PP, Heinz N, Zacher M, Diegeler A. Bio-Bentall procedure versus isolated biological aortic valve replacement: a case-match study. Eur J Cardiothorac Surg. 2015;47(6):1077-82
- Roselli E, Girardi L, Desai N, et al. First real-world multicenter series of bio-Bentall procedures with a novel pre-assembled aortic valved conduit. Podium presentation at: European Association for Cardio-thoracic Surgery; October 8-11 2025; Copenhagen, Denmark
- Praz F, Borger MA, Lanz J, et al. 2025 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2025;46(44):4635-4736
- Beaver T, Bavaria JE, Griffith B, et al. Seven-year outcomes following aortic valve replacement with a novel tissue bioprosthesis. J Thorac Cardiovasc Surg. 2024;168(3):781-791
- Kaneko T, Johnston D, Bavaria JE, Thourani V. Propensity-matched 8-year Outcomes Following Surgical Aortic Valve Replacement With Novel Calcification-resistant Versus Contemporary Tissue Bioprostheses. Heart Valve Society. 2025; Abstract
- Bartus K, Litwinowicz R, Bilewska A, et al. Final 5-year outcomes following aortic valve replacement with a RESILIA™ tissue bioprosthesis. Eur J Cardiothorac Surg. 2021;59(2):434-441
- Flameng W, Hermans H, Verbeken E, Meuris B. A randomized assessment of an advanced tissue preservation technology in the juvenile sheep model. J Thorac Cardiovasc Surg. 2015;149(1):340-5
Medical device for professional use
Medical device for professional use
For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).
PP--EU-10323 v1.0